All In Biotech

Drug Trial Radar · NCT05306340

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 373 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

373

Actual

Start

Aug 3, 2022

Primary completion

Jul 16, 2025

Study completion Jun 15, 2027

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Apr 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.

Conditions

  • Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Interventions

  • GiredestrantDrug

    Participants will receive treatment with giredestrant 30 milligrams (mg) orally once a day (QD) on Days 1-28 of each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).

  • ExemestaneDrug

    If exemestane is chosen as the physician's choice of endocrine therapy, the participant will receive exemestane at a dose of 25 mg orally once a day (QD) on Days 1-28 of each 28-day cycle or as per local label, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.

  • FulvestrantDrug

    If fulvestrant is chosen as the physician's choice of endocrine therapy, the participant will receive fulvestrant in the clinic at a dose of 500 mg intramuscularly on Day 1 and Day 15 of Cycle 1, then Day 1 of each cycle thereafter (1 cycle is 28 days) or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.

  • TamoxifenDrug

    If tamoxifen is chosen as the physician's choice of endocrine therapy, the participant will receive tamoxifen at a dose of 20 mg orally QD on Days 1-28 of each 28-day cycle or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.

  • EverolimusDrug

    Participants will receive treatment with everolimus 10 mg orally QD during each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

  • LHRH AgonistDrug

    Only premenopausal/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.

  • Dexamethasone Mouth RinseDrug

    A compounded alcohol-free mouthwash of dexamethasone (0.5 mg in 5 mL) will be supplied, where feasible. It is strongly recommended for prophylaxis or treatment of stomatitis/mucositis. Participants should use the alcohol-free mouthwash of dexamethasone four times QD for 8 weeks started concurrently with study treatment, and use it reactively thereafter with the first appearance of symptoms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT PopulationTime frame: From randomization until the first occurrence of disease progression or death from any cause, whichever occurs first (up to 42 months)

Locations

136 sites in 13 countries. Site status is shown where the registry gives one.

  • Alaska Oncology & Hematology, LLC

    Anchorage, Alaska

  • Arizona Oncology Associates, PC-CASA

    Tucson, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Alta Bates Summit Medical Center

    Berkeley, California

  • Beverly Hills Cancer Center

    Beverly Hills, California

  • TOI Clinical Research

    Cerritos, California

  • Women's Cancer Care

    Fresno, California

  • Scripps Health

    La Jolla, California

  • Los Angeles Hematology Oncology Medical Group

    Los Angeles, California

  • University of California, Irvine Medical Center

    Orange, California

  • Yale Cancer Center

    New Haven, Connecticut

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • Orlando Health Cancer Institute

    Orlando, Florida

  • Northwest Georgia Oncology Centers PC - Marietta

    Marietta, Georgia

  • Summit Cancer Care PC

    Savannah, Georgia

  • Northwestern University

    Chicago, Illinois

  • Springfield Clinic

    Springfield, Illinois

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • University of Kansas Cancer Center

    Westwood, Kansas

  • Eastern Maine Medical Center

    Brewer, Maine

  • New England Cancer Specialists

    Scarborough, Maine

  • Anne Arundel Medical Center

    Annapolis, Maryland

  • University of Maryland Greenebaum Cancer Center

    Baltimore, Maryland

  • Mercy Medical Center

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Metro-Minnesota Community Oncology Research Consortium

    Saint Louis Park, Minnesota

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists

    Omaha, Nebraska

  • Renown Regional Medical Center

    Reno, Nevada

  • Memorial Sloan Kettering - Basking Ridge

    Basking Ridge, New Jersey

  • Memorial Sloan Kettering - Monmouth

    Middletown, New Jersey

  • San Juan Oncology Associates

    Farmington, New Mexico

  • The Blavatnik Family ? Chelsea Medical Center at Mount Sinai

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Stony Brook University Medical Center

    Stony Brook, New York

  • SCRI Mark H. Zangmeister Center

    Columbus, Ohio

  • Oklahoma Cancer Specialists and Research Institute

    Tulsa, Oklahoma

  • St Charles Medical Center Bend

    Bend, Oregon

  • Abramson Cancer Center

    Philadelphia, Pennsylvania

  • UPMC Hillman Cancer Center - Magee-Women?s Hospital

    Pittsburgh, Pennsylvania

Showing 40 of 136 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.